Protocols
ABBVIE-M13-833 Phase I OPEN TO ACCRUAL *
A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric Patients with Select Relapsed or Refractory Malignancies
BCC-014-DFMO Phase II OPEN TO ACCRUAL
NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)
BCC-015 Phase II OPEN TO ACCRUAL *
Phase II Trial of Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
BMTCTN-1904 Phase II OPEN TO ACCRUAL
BMTCTN-1904 Hematopoietic Cell Transplantation Using Treosulfan-Based Conditioning for the Treatment of Bone Marrow Failure Diseases
COG-AALL1521 Phase II OPEN TO ACCRUAL
A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib with Chemotherapy in Children with De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia
COG-AALL1721 Phase II OPEN TO ACCRUAL
A Phase II Trial of Tisagenlecleucel in First-line High-risk (HR) Pediatric and Young Adult Patients with B-cell Acute Lymphoblastic Leukemia (B-ALL) Who Are Minimal Residual Disease (MRD) Positive at the End of Consolidation (EOC) Therapy
COG-AALL1821 Phase II OPEN TO ACCRUAL
AALL1821 - A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination with Nivolumab (NSC# 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >= 1 to < 31 Years Old with First Relapse
COG-AAML1921 Phase I/II OPEN TO ACCRUAL *
A Phase I/II Study of Bosutinib in Pediatric Patients with Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph+ Chronic Myeloid Leukemia
COG-ACNS1422 Phase II OPEN TO ACCRUAL *
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-RiskWNT-Driven Medulloblastoma Patients
COG-ADVL1521 Phase II OPEN TO ACCRUAL *
A Phase 2 Study of the MEK inhibitor Trametinib (IND #119346, NSC# 763093) in Children with Relapsed or Refractory Juvenile Myelomonocytic Leukemia
COG-ADVL1921 Phase I OPEN TO ACCRUAL *
Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Palbociclib (Ibrance) in Combination with Irinotecan and Temozolomide in Pediatric Patients with Recurrent or Refractory Solid Tumors
COG-AHOD1721 Phase II OPEN TO ACCRUAL *
Risk-based, Response-adapted, Phase II Open-label Trial of Nivolumab + Brentuximab Vedotin (N + Bv) for Children, Adolescents, and Young Adults with Relapsed/refractory (R/R) CD30 + Classic Hodgkin Lymphoma (cHL) After Failure of First-line Therapy, Followed by Brentuximab + Bendamustine (Bv + B) for Participants with a Suboptimal Response. CheckMate 744: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation
COG-ANBL1821 Phase II OPEN TO ACCRUAL *
A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# 141913) in Children with Relapsed, Refractory or Progressive Neuroblastoma
COG-ANHL1522 Phase II OPEN TO ACCRUAL *
A Pilot Study of Rituximab (RTX) and Third Party Latent Membrane Protein (LMP)-specific Cytotoxic T-Lymphocytes (LMP-TC, IND # 17068) in Pediatric Solid Organ Recipients (SOT) with EBV-Positive CD20-Positive Post-Transplant Lymphoproliferative Disease (PTLD)
COG-APEC1621A Phase II OPEN TO ACCRUAL *
NCI-COG Pediatric MATCH (Molecular Analysis For Therapy Choice)- Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients with Tumors Harboring Actionable NTRK Fusions
COG-APEC1621D Phase II OPEN TO ACCRUAL *
NCI-COG PEDIATRIC MATCH (Molecular Analysis for Therapy Choice)-Phase 2 Subprotocol of LY3023414 in Patients with Solid Tumors
COG-APEC1621F Phase II OPEN TO ACCRUAL *
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients with Tumors Harboring ALK or ROS1 Genomic Alterations
COG-APEC1621K Phase II OPEN TO ACCRUAL *
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients with Tumors Harboring IDH1 Mutations
COG-AREN1721 Phase II OPEN TO ACCRUAL *
A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs Single Agent Axitinib or Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups
COG-AREN1921 Phase II OPEN TO ACCRUAL *
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
COG-ARST1921 Phase II OPEN TO ACCRUAL *
A Safety, Pharmacokinetic and Efficacy Study of a Gamma-Secretase Inhibitor, Nirogacestat (PF-03084014; IND# 146375), in Children and Adolescents with Progressive, Surgically Unresectable Desmoid Tumors
IIT-TALANO-CART-ALL Phase I OPEN TO ACCRUAL
Phase 1 Study of Redirected Autologous T Cells Engineered to Contain an Anti-CD19 and Anti-CD20 scFv Coupled to CD3-zeta; and 4-1BB Signaling Domains in Pediatric and Young Adult Patients with Relapsed and/or Refractory CD19 or CD20 B-cell Acute Lymphoblastic Leukemia
PBMTC-ONC1401 Phase II OPEN TO ACCRUAL
The Role of KIR-favorably Mismatched Haploidentical Transplantation and KIR-polymorphisms in Determining Outcomes of Children with ALL/AML/MDS Undergoing Allogeneic Hematopoietic Cell Transplantation
PIDTC-CSIDE Phase II OPEN TO ACCRUAL *
A randomized trial of low versus moderate exposure busulfan for infants with severe combined immunodeficiency (SCID) receiving TCR alpha beta+/CD19+ depleted transplantation: A Phase II study by the Primary Immune Deficiency Treatment Consortium (PIDTC) and Pediatric Blood and Marrow Transplant Consortium (PBMTC) PIDTC CSIDE Protocol (Conditioning SCID Infants Diagnosed Early) PBMTC NMD 1801
PTCTC-ONC1701-ENDRAD Phase II OPEN TO ACCRUAL
A Phase II Pilot Trial to Estimate Survival after a Non-total Body Irradiation (TBI) Based Conditioning Regimen in Patients Diagnosed with B-acute Lymphoblastic Leukemia (ALL) Who are Pre-allogeneic Hematopoietic Cell Transplantation (HCT) Next-generation-sequence (NGS) Minimal Residual Disease (MRD) Negative
SPOC-2012-001 Phase I OPEN TO ACCRUAL
Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors
SPRINGWORKS-MEK-NF-201 Phase II OPEN TO ACCRUAL
A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Patients with Neurofibromatosis Type 1 (NF1) associated Inoperable Plexiform Neurofibromas (PNs) that are Progressing and/or Causing Significant Morbidity
TACL-MARQIBO Phase I OPEN TO ACCRUAL *
A Pilot Study of Vincristine Sulfate Liposome Injection (Marqibo®) in Combination with UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults with Relapse of Acute Lymphoblastic Leukemia
TACL-ONYX-CFZ008 Phase I OPEN TO ACCRUAL
Phase 1b Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia